There are major differences between oncologists and primary care physicians regarding knowledge, attitudes, and practices required to care for American's 12 million cancer survivors...
Scientists Discover New Pathway To Potential Therapies For Advanced Prostate Cancer
7/26/2011
UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously...
Specialized Regulatory T Cell Stifles Antibody Production Centers
7/26/2011
A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, a team led by scientists at The University of Texas MD Anderson Cancer Center reported online in the journal Nature Medicine...
Universal Donor Immune Cells
7/26/2011
One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells...
Record Number Of Abstracts Submitted To CTRC-AACR San Antonio Breast Cancer Symposium
7/26/2011
This year's CTRC-AACR San Antonio Breast Cancer Symposium received 1,641 abstract submissions before their deadline closed on June 21, 2011, an increase over the previous 2009 record of 1,464...
A considerable number of doctors do not appear to offer ovarian and breast cancer counseling, as well as testing services to women at high risk, researchers from the CDC (Centers for Disease Control and Prevention) report in the journal Cancer. Females with the BRCA1 or BRCA2 gene have a much higher chance of developing ovarian or breast cancer compared to other women...
Pharmalucence, Inc. has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients. Sulfur Colloid Injection (SCI) is a radioactive tracer manufactured by Pharmalucence which labels lymph nodes with a radioactive signal...
Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA® (abiraterone acetate) under an accelerated regulatory review procedure...
Blacks Less Likely To Survive Advanced Breast Cancer Regardless Of Radiation Therapy
7/25/2011
UC Davis researchers have found that blacks are more likely than patients from other racial and ethnic groups to die from advanced breast cancer and that the disparity cannot be explained by the fact that blacks are less likely to receive radiation therapy, a standard treatment for advanced disease...
Predicting Second Cancers After Radiation For Children With Hodgkin Lymphoma
7/25/2011
A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment...